N Engl J Med 2012;367:616-24. Dae youn.kim/Prof.Chang hyun Lee.

Slides:



Advertisements
Similar presentations
Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Advertisements

Peter R. McNally, DO, FACP, FACG Lone Tree, Colorado
A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.
Emerging treatments in Crohn’s disease and ulcerative colitis
Future Therapies for the Inflammatory Bowel Diseases Ryan W. Stidham, MD Crohn’s and Colitis Program University of Michigan Health System Ann Arbor, Michigan.
Gazing into the Crystal Ball: How will Evolving Future Therapies Change how we Position Biologics for Use in IBD? William J. Sandborn, MD Professor & Chief,
Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.
Randomized, double-blind, multicenter, controlled trial.
Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
SECONDARY PREVENTIONS Jaimon Stucki MS-1 PSCOM. Blood Draw.
Rimonabant in Obesity Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres RIO LIPIDS Trial.
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
P1586 THE FIRST JAK1-SELECTIVE INHIBITOR, FILGOTINIB, DISPLAYS SIMILAR MOLECULAR ACTIVITY IN THE GUT OF MICE WITH DSS-INDUCED COLITIS AND IN CULTURES OF.
STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.
Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.
Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised,placebo-controlled.
William J. Sandborn, M.D., Brian G. Feagan, M.D., Paul Rutgeerts, M.D., Ph.D., Stephen Hanauer, M.D., Jean-Frederic Colombel, M.D., Bruce E. Sands, M.D.,
Dienst gastro-enterologie, UZ Gent
LANCET 2011; 378: 2005–12 R3 Kim Dong Hyun / Prof. Chin Sang Ouk Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine.
Xavier Roblin, MD, PhD 1, M. Rinaudo, MD 2, E. Del Tedesco, MD 1, J.M. Phelip, MD, PhD 1, C. Genin, MD, PhD 2, L. Peyrin-Biroulet, MD, PhD 3 and S. Paul,
Am J Gastroenterol 2010; 105:1820–1829 F1 박재현. Background Background A novel mouse line with defects in both transforming growth factor- β type II receptor.
MIGUEL REGUEIRO, WOLFGANG SCHRAUT, LEONARD BAIDOO, KEVIN E. KIP, ANTONIA R. SEPULVEDA, MARILYN PESCI, JANET HARRISON, SCOTT E. PLEVY GASTROENTEROLOGY 2009;136:441–450.
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.
Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Clinical and Immunologic Assessment of Patients With.
Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi: /annrheumdis
Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.
Learning Objectives Describe the relationship between the JAK-STAT signaling pathway and pathogenesis of inflammatory bowel disease. Summarize the latest.
HOPE: Heart Outcomes Prevention Evaluation study
Copyright © 2002 American Medical Association. All rights reserved.
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Oxford Niacin Trial.
Onderzoek met geneesmiddelen
Optimizing Use of Biological Agents in Ulcerative Colitis
Nat. Rev. Rheumatol. doi: /nrrheum
Abatacept for Crohn's Disease and Ulcerative Colitis
The Hypertension in the Very Elderly Trial (HYVET)
Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.
Illustrations in Ulcerative Colitis
Volume 153, Issue 1, Pages e6 (July 2017)
John J. O'Shea, Robert Plenge  Immunity 
Methotrexate for Ulcerative Colitis: To Use or Not to Use?
Volume 146, Issue 1, Pages e1 (January 2014)
Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study  William J. Sandborn, William F. Stenson,
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)
Volume 149, Issue 7, Pages e2 (December 2015)
Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis  Gary R. Lichtenstein,
Volume 156, Issue 4, Pages e18 (March 2019)
Volume 148, Issue 4, Pages e2 (April 2015)
Clinical Gastroenterology and Hepatology
Leveraging Omics Biomarker in Early Clinical Trials - Concept, Utility and Impact on Decision Making Weidong Zhang Pfizer Inc. July 30, 2018.
Major classes of drugs to reduce lipids
Volume 132, Issue 1, Pages (January 2007)
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Presentation data from US VICTORY Consortium
Volume 134, Issue 3, Pages (March 2008)
Crohn’s Disease Biologic Pathway
Clinical Gastroenterology and Hepatology
Treatment Advances for RA
Meet the JAKs.
Study design. Study design. Patients who completed the 8-week induction study and achieved clinical response-100 (decrease in Crohn's disease activity.
Presentation transcript:

N Engl J Med 2012;367: Dae youn.kim/Prof.Chang hyun Lee

 Tofacitinib is a selective oral inhibitor of the Janus kinase family of kinases, including JAK1 and 3.  Janus kinase mediates signal transduction activity through the common gamma chain of the surface receptors for multiple cytokines, including interleukins 2,4,7,9,15,21.  Cytokines activate JAK/STAT signaling pathway, it is known to function in lymphocyte activation, function, and proliferation.  Blocking of a common signaling molecule used by these cytokines suppress both T and B cells while maintaining regulatory T-cell function.  Tofacitinib has shown efficacy for prevention of organ allograft rejection and in the treatment of rhematoid arthritis and psoriasis. O’Shea J J Ann Rheum Dis 2004;63:ii67-ii71 (Tofacitinib)

 This paper evaluates the efficacy of Tofacitinib in patients with moderately to severely active ulcerative colitis.

Study patientsStudy design  8-week  Multicenter, randomized  Double-blind  Placebo-controlled  ≥18 years old  Diagnosis of UC for ≥3 months  6-12 on Mayo scale  Moderately or severely active disease on sigmoidoscopy  2:2:2:3:3 ratio at a dose of 0.5mg, 3mg, 10mg, 15mg or placebo  Administered twice daily

 The Mayo score was determined at baseline and 8 weeks. A partial Mayo score (based on three of the four questions [lacking the endoscopic findings subscore], for a range of 0 to 9), was determined at 0, 2, 4, and 8 weeks.  Colonoscopy or flexible sigmoidoscopy was performed at baseline and again at 8 weeks. Clinical response was defined as a decrease from baseline in the total Mayo score — defined as an absolute decrease by at least 3 points and a relative decrease by at least 30% — with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1.  Clinical remission was defined as a total Mayo score of 0 to 2, with no individual subscore exceeding 1.  Endoscopic response was defined as a decrease from baseline in the endoscopy subscore by at least 1, and endoscopic remission was defined as an endoscopy subscore of 0.  The health-related quality of life was measured with the use of the Inflammatory Bowel Disease Questionnaire (with scores ranging from 0 to 224 points and scores of 170 points or more indicating clinically inactive disease).

 The primary efficacy end point was a clinical response at 8 weeks.  Secondary efficacy end points included clinical remission at 8 weeks; endoscopic response at 8 weeks; endoscopic remission at 8 weeks; change from baseline in the partial Mayo score at 2, 4, and 8 weeks; change from baseline in the total Mayo score at 8 weeks; change from baseline in the CRP concentration at 4 and 8 weeks; and the change from baseline in the fecal calprotectin concentration at 2, 4, and 8 weeks.  The changes from baseline in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol concentrations and serum creatinine concentrations at 8 and 12 weeks were also determined.

 Patients with moderately or severely active ulcerative colitis treated with tofacitinib had a clinical response and clinical remission more frequently than those receiving placebo